Endocrine Abstracts

13 year old lad diagnosed to have type 1 diabetes at the age of 18 months, moved to our area when he was about 5 years of age coming from a family with complex social background. His diabetes control has always been challenging with HBA1c generally above 70 mmol/mol and only occasionally going below 70. He was tried on multiple daily insulin (MDI), then insulin pump and then back to MDI –currently he is on Insulin degludec. He had recurrent admissions to the paediatric wa...

Our diabetes service was successful in the application to participate in the RCPCH Quality improvement initiative (2018–2019).Our aims were: To identify strategies to enable teams to work collaboratively across multiple trust sites, 30 miles apart, covering a 50 mile radius. To undertake and complete projects in a timely and efficient manner to provide an equitable service across sites. To help maintain consistent improvement in HbA1c outcomes. To i...

Mauriac syndrome is a rare complication of poorly controlled type 1 diabetes (T1D) characterized by growth failure, hepatomegaly, elevated transaminases and cushingoid features. We report a case of an eleven year old boy with Mauriac syndrome.Case Study: An eleven year old Caucasian boy, known to have T1D from 7 years of age with poor glycaemic control and high HbA1c noted to have abdominal distension with hepatomegaly at his clinic visit. It was also no...

Introduction: Children on long-term steroid replacement for adrenal insufficiency may need emergency administration of i.m. hydrocortisone when unwell. There was a recent incident in Wales in terms of the out of hospital administration of hydrocortisone by ambulance crew. A child on long-term hydrocortisone for hypopituitarism became unwell at school. When the ambulance crew attended, it was brought to our attention that they cannot administer i.m. hydrocortisone unless the un...

Introduction: Continuous subcutaneous insulin infusion (CSII) or ‘pump’, therapy is used for intensification of insulin therapy. NICE guideline 2008 recommends CSII as an option for adults / children 12 years or older with insulin dependent diabetes mellitus (IDDM), when multiple daily injection (MDI) insulin therapy results in disabling hypoglycaemia/fails to reduce HbA1c levels below 8.5%, and for children below 12 years whenever MDI is impractical or inappropriate...